Springer Amends Stake in Cartesian Therapeutics

TL;DR

Springer filed an amendment to his 13D for Cartesian Therapeutics, Inc. on 10/4/24.

AI Summary

On October 4, 2024, Timothy A. Springer filed Amendment No. 16 to Schedule 13D for Cartesian Therapeutics, Inc. This filing indicates a change in beneficial ownership of the company's common stock. The filing was made on October 4, 2024, with the SEC.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in major shareholder sentiment or strategy, potentially impacting the stock price.

Risk Assessment

Risk Level: medium — Schedule 13D filings often involve significant shareholders, and changes in their holdings can indicate potential strategic moves or market sentiment shifts.

Key Players & Entities

• Timothy A. Springer (person) — Filing person with a change in beneficial ownership
• Cartesian Therapeutics, Inc. (company) — Subject company of the filing
• October 4, 2024 (date) — Date of the filing
• Amendment No. 16 (document) — Specific amendment to the Schedule 13D

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $17.17 — of 5,514 Shares at prices ranging from $17.17 to $17.50 per share for an aggregate pu
• $17.50 — Shares at prices ranging from $17.17 to $17.50 per share for an aggregate purchase pri
• $95,821 — gregate purchase price of approximately $95,821. Dr. Springer used personal funds for s
• $17.76 — f 119,906 Shares at prices ranging from $17.76 to $22.00 per share for an aggregate pu
• $22.00 — Shares at prices ranging from $17.76 to $22.00 per share for an aggregate purchase pri
• $2,384,711 — gregate purchase price of approximately $2,384,711. Dr. Springer used personal funds for s
• $20.87 — of 80,301 Shares at prices ranging from $20.87 to $24.00 per share for an aggregate pu
• $24.00 — Shares at prices ranging from $20.87 to $24.00 per share for an aggregate purchase pri
• $1,813,010 — gregate purchase price of approximately $1,813,010. Dr. Springer used personal funds for s

Filing Documents

• ea0216898-13da16spring_cart.htm (SC 13D/A) — 79KB
• 0001213900-24-085663.txt ( ) — 80KB

Source

Item 3. Source and Amount of Funds or Other Consideration .

of the Schedule 13D is hereby amended to be supplemented by

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following: On October 2, 2024, TAS distributed an aggregate of 2,119,193 Shares and 133,632 warrants held by it to Dr. Springer and Dr. Lu. TAS distributed 1,801,314 Shares and 113,587 warrants to Dr. Springer and 317,879 Shares and 20,045 warrants to Dr. Lu. In open market purchases on October 2, 2024, Dr. Springer acquired an aggregate of 5,514 Shares at prices ranging from $17.17 to $17.50 per share for an aggregate purchase price of approximately $95,821. Dr. Springer used personal funds for such acquisitions. In open market purchases on October 3, 2024, Dr. Springer acquired an aggregate of 119,906 Shares at prices ranging from $17.76 to $22.00 per share for an aggregate purchase price of approximately $2,384,711. Dr. Springer used personal funds for such acquisitions. In open market purchases on October 4, 2024, Dr. Springer acquired an aggregate of 80,301 Shares at prices ranging from $20.87 to $24.00 per share for an aggregate purchase price of approximately $1,813,010. Dr. Springer used personal funds for such acquisitions. CUSIP No . 816212302 13D Page 6 of 7 Pages Item 5. Interest in Securities of the Issuer .

of Schedule 13D is hereby amended and restated in full as follows

Item 5 of Schedule 13D is hereby amended and restated in full as follows: The information set forth under Item 3 and the cover page of the Schedule 13D is incorporated herein by reference into this Item 5. (a) The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person’s cover page to this Statement, are based on a total of 23,893,525 Shares issued and outstanding as of September 25, 2024, as reported on the Issuer’s Current Report on Form 8-K, dated September 26, 2024. All of the Share numbers reported below, and on each Reporting Person’s cover page to this Statement, are as of October 4, 2024. The Reporting Persons, in the aggregate, beneficially own 9,047,688 Shares, representing approximately 37.6% of such class of securities. Dr. Springer is the beneficial owner of a total of 9,047,688 Shares, representing approximately 37.6% of the outstanding Shares and consisting of (i) 8,017,833 Shares held directly, (ii) 113,587 Shares underlying warrants exercisable within 60 days of October 4, 2024 held directly, (iii) 2,322 Shares issuable upon exercise of outstanding options exercisable within 60 days of October 4, 2024, (iv) 529,798 Shares held by TAS, (v) 33,408 Shares underlying warrants exercisable within 60 days of October 4, 2024 held by TAS, (vi) 330,695 Shares held by Dr. Lu and (vii) 20,045 Shares underlying warrants exercisable within 60 days of October 4, 2024 held by Dr. Lu. TAS is the beneficial owner of a total of 563,206 Shares, representing approximately 2.4% of the outstanding Shares and consisting of (i) 529,798 Shares and (ii) 33,408 Shares underlying warrants exercisable within 60 days of October 4, 2024. TAS holds all such Shares directly. Dr. Springer is the sole managing member of TAS. Dr. Lu is the beneficial owner of a total of 350,740 Shares, representing approximately 1.5% of the outstanding Shares and consisting of (i) 330,695 Shares held directly and (ii) 20,045 Shares underlying wa

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: October 4, 2024 /s/ Timothy A. Springer Timothy A. Springer /s/ Chafen Lu Chafen Lu TAS Partners LLC By: /s/ Timothy A. Springer Name: Timothy A. Springer Title: Manager

View Full Filing

View this SC 13D/A filing on SEC EDGAR